Innate Pharma (IPHA) Debt Ratio (2017 - 2025)

Innate Pharma (IPHA) has disclosed Debt Ratio for 8 consecutive years, with 0.28 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Debt Ratio rose 22.56% year-over-year to 0.28, compared with a TTM value of 0.04 through Dec 2024, up 0.59%, and an annual FY2024 reading of 0.28, up 22.56% over the prior year.
  • Debt Ratio was 0.28 for Q4 2024 at Innate Pharma, up from 0.23 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.28 in Q4 2024 and bottomed at 0.06 in Q4 2020.
  • Average Debt Ratio over 5 years is 0.19, with a median of 0.21 recorded in 2022.
  • The sharpest move saw Debt Ratio soared 166.44% in 2021, then increased 7.41% in 2023.
  • Year by year, Debt Ratio stood at 0.06 in 2020, then skyrocketed by 166.44% to 0.17 in 2021, then increased by 28.15% to 0.21 in 2022, then increased by 7.41% to 0.23 in 2023, then increased by 22.56% to 0.28 in 2024.
  • Business Quant data shows Debt Ratio for IPHA at 0.28 in Q4 2024, 0.23 in Q4 2023, and 0.21 in Q4 2022.